Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS

The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives

Cardiovascular risk factors cluster in hyperandrogenic women - including those presenting with the polycystic ovary syndrome - in association with insulin resistance, obesity, and other metabolic disorders.

The present clinical trial intends to compare the effects of oral contraceptives and metformin on PCOS patients, focusing on classic and non-classic cardiovascular risk markers and indexes of cardiovascular performance, in order to whether or not, as suspected by previous data obtained in non-hyperandrogenic women, oral contraceptives worsen the cardiovascular risk profile of PCOS women, favoring the use of metformin if the latter actually ameliorates such a risk.

Inclusion Criteria:

• Women of fertile age presenting with PCOS
• Non-hyperandrogenic women of fertile age (these women will not receive the interventions and will serve only to obtain normative data for some variables)

Exclusion Criteria:

• Severe disease not related to the condition under study
• Pregnancy
• Medical or surgical treatment of PCOS during the previous 3 months
• Contraindication for the use of oral contraceptives or metformin
• Inability to understand the proposal of the study precluding effective informed consent
• Minors who are not accompanied by their legal representative